202 related articles for article (PubMed ID: 8584657)
1. Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to 1-deprenyl therapy.
Ruehl WW; Bruyette DS; DePaoli A; Cotman CW; Head E; Milgram NW; Cummings BJ
Prog Brain Res; 1995; 106():217-25. PubMed ID: 8584657
[No Abstract] [Full Text] [Related]
2. The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs.
Studzinski CM; Araujo JA; Milgram NW
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):489-98. PubMed ID: 15795058
[TBL] [Abstract][Full Text] [Related]
3. Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging.
Araujo JA; Studzinski CM; Milgram NW
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):411-22. PubMed ID: 15795050
[TBL] [Abstract][Full Text] [Related]
4. Selegiline for Alzheimer's disease.
Birks J; Flicker L
Cochrane Database Syst Rev; 2000; (2):CD000442. PubMed ID: 10796544
[TBL] [Abstract][Full Text] [Related]
5. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
Filip V; Kolibás E
J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of vascular disease in dementia: what does industry want to know?
Wren PB; Hill D; Lockhart A
Clin Sci (Lond); 2017 May; 131(9):799-802. PubMed ID: 28424374
[TBL] [Abstract][Full Text] [Related]
7. Debate regarding news story on cognitive dysfunction in dogs and cats.
O'Toole D
J Am Vet Med Assoc; 1998 Jul; 213(2):199-201. PubMed ID: 9676585
[No Abstract] [Full Text] [Related]
8. Hypertension, cognitive decline, and dementia: an epidemiological perspective.
Tzourio C
Dialogues Clin Neurosci; 2007; 9(1):61-70. PubMed ID: 17506226
[TBL] [Abstract][Full Text] [Related]
9. The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases.
Knoll J
J Neural Transm Suppl; 1993; 40():69-91. PubMed ID: 8294902
[TBL] [Abstract][Full Text] [Related]
10. The role of human cognitive neuroscience in drug discovery for the dementias.
Wesnes KA; Edgar CJ
Curr Opin Pharmacol; 2014 Feb; 14():62-73. PubMed ID: 24565014
[TBL] [Abstract][Full Text] [Related]
11. A report from the 13th International Conference on Alzheimer's Disease and Related Disorders (ICAD) (July 10-15, 2010-Honolulu, Hawaii, USA).
Rabasseda X
Drugs Today (Barc); 2010 Nov; 46(11):875-87. PubMed ID: 21225026
[TBL] [Abstract][Full Text] [Related]
12. Dogs with cognitive dysfunction syndrome: a natural model of Alzheimer's disease.
Bosch MN; Pugliese M; Gimeno-Bayón J; Rodríguez MJ; Mahy N
Curr Alzheimer Res; 2012 Mar; 9(3):298-314. PubMed ID: 21875411
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic actions of L-deprenyl in dogs: a model of human brain aging.
Ruehl WW; Neilson J; Hart B; Head E; Bruyette DS; Cummings BJ
Adv Pharmacol; 1998; 42():316-9. PubMed ID: 9327904
[No Abstract] [Full Text] [Related]
14. The rate of decline in function in Alzheimer's disease and other dementias.
Mitnitski AB; Graham JE; Mogilner AJ; Rockwood K
J Gerontol A Biol Sci Med Sci; 1999 Feb; 54(2):M65-9. PubMed ID: 10051857
[TBL] [Abstract][Full Text] [Related]
15. [Clinical-therapeutic study of dementia in people with Down syndrome and the effectiveness of donepezil in this population].
Boada-Rovira M; Hernández-Ruiz I; Badenas-Homiar S; Buendía-Torras M; Tárraga-Mestre L
Rev Neurol; 2005 Aug 1-15; 41(3):129-36. PubMed ID: 16047294
[TBL] [Abstract][Full Text] [Related]
16. Normal ageing, impaired cognitive function, and senile dementia of the Alzheimer's type: a continuum?
Brayne C; Calloway P
Lancet; 1988 Jun; 1(8597):1265-7. PubMed ID: 2897526
[TBL] [Abstract][Full Text] [Related]
17. [Dementia and cognitive impairment pattern: its association with epsilon4 allele of apolipoprotein E gene].
Rosich-Estragó M; Figuera-Terré L; Mulet-Pérez B; Arrufat-Cardús MT; Pascual San Emeterio A; Arbeola-Rigau I; Labad-Alquézar A; Vilella-Cuadrada E
Rev Neurol; 2004 May 1-15; 38(9):801-7. PubMed ID: 15152345
[TBL] [Abstract][Full Text] [Related]
18. L-deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results.
Burke WJ; Ranno AE; Roccaforte WH; Wengel SP; Bayer BL; Willcockson NK
J Am Geriatr Soc; 1993 Apr; 41(4):367-70. PubMed ID: 8463521
[TBL] [Abstract][Full Text] [Related]
19. Brief information on an early phase-II study with deprenyl in demented patients.
Martini E; Pataky I; Szilágyi K; Venter V
Pharmacopsychiatry; 1987 Nov; 20(6):256-7. PubMed ID: 3124143
[TBL] [Abstract][Full Text] [Related]
20. Cognitive effects of L-deprenyl in Alzheimer's disease.
Tariot PN; Sunderland T; Weingartner H; Murphy DL; Welkowitz JA; Thompson K; Cohen RM
Psychopharmacology (Berl); 1987; 91(4):489-95. PubMed ID: 3108930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
